Sunway Healthcare Holdings Berhad

Sunway Healthcare is the dataset's flagship and its most demanding valuation. The asset is genuinely high quality: one of Malaysia's largest private hospital groups, revenue compounding 31.9% a year to RM1.85bn on a rock-steady 64% gross margin, RM420m of operating cash flow, and a RM2.89bn equity base — the profile that drew 20 cornerstone investors and RM11.7bn of bookbuild demand. The problem is arithmetic. PATAMI compounded only 10.8% a year to RM257.5m because margins compressed as the network scaled, so the business earns an 8.9% ROE, yet the RM1.45 price capitalises it at RM16.7bn — roughly 64.8x FYE2024 earnings and 5.37x pro forma book, the richest multiple anywhere in this coverage. The proceeds plan is sensible for a platform operator (66.5% into hospital-capacity expansion, 29.9% redeeming Sukuk), but that expansion is a four-to-six-year build, so the earnings that would justify the multiple are years out and exposed to capex, licensing and staffing risk. The 5.57x retail tranche and a 17% debut show the market is willing to pay for scarcity and quality. This is a long-duration platform bet where the entry price already discounts a great deal of the future build. Principal risk is that a single-digit-ROE business priced at ~65x has no tolerance for delay.